Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral BG9928 in Patients With Heart Failure and Renal Insufficiency
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Tonapofylline (Primary)
- Indications Heart failure
- Focus Adverse reactions
- Acronyms POSEIDON
- Sponsors Biogen
- 22 Jan 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 17 Feb 2009 Actual initiation date (Feb 2009) added as reported by ClinicalTrials.gov.
- 17 Feb 2009 Planned end date changed from 1 Aug 2010 to 1 Jan 2011 as reported by ClinicalTrials.gov.